We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Clinical outcomes of lung- transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
- Authors
Kanafani, Zeina A.; Klepser, Michael E.
- Abstract
Although voriconazole is widely considered to be the drug of choice for the treatment of invasive pulmonary aspergillosis, it may take an unacceptable length of time to achieve optimal blood concentrations. As a result, some clinicians elect to use a bridging agent such as caspofungin in combination with voriconazole in order to improve early response. In this study, the authors retrospectively identified patients who had undergone lung transplantation and received voriconazole and caspofungin between 2002 and 2008. Fifteen patients were identified, of whom 14 had a complete response. It was noted that the median time taken to achieve a target voriconazole blood level of ≥1 mg/L was 12.3 days. This time was appreciably longer among patients with cystic fibrosis compared with those who underwent lung transplantation for other reasons (14.9 days vs. 8.3 days). Combination of voriconazole and caspofungin may be useful in providing coverage against Aspergillus infection during a period when voriconazole levels may be subtherapeutic.
- Subjects
ANTIFUNGAL agents; PULMONARY aspergillosis; LUNG transplantation; COMPLICATIONS from organ transplantation; COMBINATION drug therapy; ASPERGILLUS; THERAPEUTICS
- Publication
Journal of Invasive Fungal Infections, 2010, Vol 4, Issue 2, p73
- ISSN
1753-3783
- Publication type
Article